The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Publication|Articles|September 28, 2023
- Pharmaceutical Technology, October 2023
- Volume 47
- Issue 10
Multifunctional Excipient
Author(s)Pharmaceutical Technology Editors
Univar Solutions' Grace Syloid FP and XDP Silica is a multifunctional excipient designed to solve powder flow and caking challenges in various pharmaceutical applications.
Univar Solutions' Grace Syloid FP and XDP Silica is a multifunctional excipient designed to solve powder flow and caking challenges in various pharmaceutical applications. Manufactured in the United States, Syloid silica is an engineered hydrated silicon dioxide produced under controlled conditions. It meets US Pharmacopeia, European Medicines Agency, Health Canada, and Brazilian Health Regulatory Agency requirements.
Syloid silica’s design combines adsorption capacity, particle size, density, and internal surface area to provide multifunctional benefits or to optimize an application. This is intended to help minimize the number of excipients used and simplify the complexity of formulations while expediting manufacturing and ultimately improving the efficacy of the final dosage form.
Articles in this issue
about 3 years ago
Driving Dosage Form Developmentsabout 3 years ago
Considering Advances in Twin-Screw Extrusion for Solid-Dosage Drugsabout 3 years ago
Growing Opportunities in Outsourced Biopharma APIsabout 3 years ago
Green-by-Design Small-Molecule API Synthesisabout 3 years ago
Losing Weight, Gaining Valueabout 3 years ago
Washington, DC Houses mRNA Leadershipabout 3 years ago
Renewed Hope for Alzheimer’sabout 3 years ago
Complying with Compendial RequirementsRelated to this article
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.